Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection

Creative Commons License

Pepeler M. S., YILDIZ Ş., YEGİN Z. A., ÖZKURT Z. N., GÜZEL TUNÇCAN Ö., ERBAŞ G., ...Daha Fazla

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, cilt.12, sa.9, ss.799-805, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 9
  • Basım Tarihi: 2018
  • Doi Numarası: 10.3855/jidc.9961
  • Dergi Adı: JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.799-805
  • Anahtar Kelimeler: invasive fungal infection, antifungal prophylaxis, voriconazole, amphotericin B, LIPOSOMAL AMPHOTERICIN-B, RISK-FACTORS, HEMATOLOGICAL MALIGNANCIES, MARROW-TRANSPLANTATION, ASPERGILLOSIS, DISEASES, VORICONAZOLE, EXPERIENCE, THERAPY, HISTORY
  • Gazi Üniversitesi Adresli: Evet

Özet

Introduction: Invasive fungal infection (IFI) is a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. A previous history of IFI is not an absolute contraindication for allo-HSCT, particularly in the era of secondary antifungal prophylaxis (SAP). Prompt diagnosis and therapy are essential for HSCT outcome.